Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Vertex Partnerships Target Hepatitis C
by Michael McCoy
November 5, 2012
| A version of this story appeared in
Volume 90, Issue 45
Vertex Pharmaceuticals is teaming up with Johnson & Johnson and GlaxoSmithKline in separate partnerships aimed at developing an all-oral hepatitis C treatment. Vertex and J&J’s Janssen Pharmaceuticals unit will conduct a Phase II study of a treatment combining Vertex’ polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir. Vertex and GSK will study a combination of VX-135 with GSK’s NS5A inhibitor GSK2336805. Last year, FDA approved Vertex’ Incivek protease inhibitor, but, like other hepatitis C drugs, it must be administered with unpleasant interferon injections.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter